WO2021075073A1 - 組成物、製造方法及び使用 - Google Patents

組成物、製造方法及び使用 Download PDF

Info

Publication number
WO2021075073A1
WO2021075073A1 PCT/JP2020/012524 JP2020012524W WO2021075073A1 WO 2021075073 A1 WO2021075073 A1 WO 2021075073A1 JP 2020012524 W JP2020012524 W JP 2020012524W WO 2021075073 A1 WO2021075073 A1 WO 2021075073A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
powder
composition
bacterial
bacterial powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/012524
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
健吾 藤井
宮内 浩文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020227003277A priority Critical patent/KR20220026595A/ko
Priority to CN202080057079.5A priority patent/CN114222503A/zh
Priority to KR1020267008192A priority patent/KR20260043146A/ko
Priority to EP20877757.3A priority patent/EP4046499B1/en
Priority to JP2021552091A priority patent/JP7086309B2/ja
Priority to CN202211398838.1A priority patent/CN115624181A/zh
Priority to NZ784460A priority patent/NZ784460B2/en
Priority to AU2020366736A priority patent/AU2020366736B2/en
Priority to CN202510128251.6A priority patent/CN120570388A/zh
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Priority to ES20877757T priority patent/ES2997284T3/es
Priority to PL20877757.3T priority patent/PL4046499T3/pl
Priority to US16/987,061 priority patent/US20210113631A1/en
Publication of WO2021075073A1 publication Critical patent/WO2021075073A1/ja
Priority to US17/688,035 priority patent/US20220193159A1/en
Anticipated expiration legal-status Critical
Priority to JP2022091694A priority patent/JP7575424B2/ja
Priority to JP2024181969A priority patent/JP2025010582A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/26—Compounds containing phosphorus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/015—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A23L29/04—Fatty acids or derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/20—Ingredients acting on or related to the structure
    • A23V2200/222—Emulsifier
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/1578—Calcium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/206—Bacterial extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/50—Polysaccharides, gums
    • A23V2250/51—Polysaccharide
    • A23V2250/5108—Cellulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus

Definitions

  • the present invention relates to compositions, production methods and uses.
  • the present application claims priority based on provisional patent application No. 629163646 filed in the United States on October 17, 2019, the contents of which are incorporated herein by reference.
  • Bacteria have beneficial effects on human health such as constipation and diarrhea improvement effect, lactose intolerance improvement effect, infection protection and allergy suppression effect by improving immune function, arteriosclerosis prevention effect, and antitumor effect.
  • a product called oil drop in which bacterial powder is suspended in fatty oil has been sold.
  • oil drops it is desirable that the bacterial powder is evenly dispersed in the fatty oil, but the bacterial powder precipitates and solidifies at the bottom of the container, eventually forming a deposit that makes it difficult to redisperse the bacterial powder ( (Caking) may occur.
  • Patent Document 1 describes a supplement composition containing one or more or one or more probiotic bacteria, an oil, and anhydrous calcium hydrogen phosphate.
  • the supplement composition has been described to maintain the viability of probiotic bacteria.
  • This supplement composition is a suspension using oil as a dispersion medium.
  • the carrier caking did not occur. From the results of this study, the present inventors considered that the caking of the bacterial powder in the oil drop was caused by the bacterial cells themselves contained in the bacterial powder.
  • An object of the present invention is to provide a composition, a production method, and a use containing bacterial powder and fatty oil and suppressing caking of the bacterial powder.
  • a composition containing bacterial powder, a fatty oil, and at least one selected from the group consisting of fine powders and surfactants [2] The composition according to [1], which is a suspension. [3] The bacterial powder contains at least one selected from the group consisting of live lactic acid bacteria, dead lactic acid bacteria, live bifidobacteria, and dead bifidobacteria. The composition according to [1] or [2]. [4] The composition according to any one of [1] to [3], wherein the fine powder contains at least one selected from the group consisting of microcrystalline cellulose and tricalcium phosphate.
  • composition [5] The method according to any one of [1] to [4], wherein the surfactant comprises at least one selected from the group consisting of an anionic surfactant and a nonionic surfactant having an HLB value of less than 7.
  • the composition according to [5] which comprises at least one selected from the group consisting of glycerin fatty acid esters having an HLB value of less than 7.
  • Bacterial powder, fatty oil, and at least one selected from the group consisting of fine powder and surfactant are mixed in any order, or in a suspension containing bacterial powder and fatty oil.
  • the present invention it is possible to provide a composition, a production method and use containing bacterial powder and fatty oil and suppressing caking of the bacterial powder.
  • the composition of the present invention caking of bacterial powder is suppressed, and bacterial powder is easily dispersed in the fatty oil which is a dispersion medium.
  • Caking means that in a suspension containing bacterial powder, the bacterial powder precipitates and solidifies to form a deposit that is difficult to redisperse. That is, caking means that a sediment is formed that is difficult to redisperse while precipitating and solidifying, and even if it is precipitated and solidified, it cannot be said to be caking if redispersion is possible.
  • the numerical range represented by "-" includes the upper limit value and the lower limit value of the numerical range.
  • composition contains bacterial powder, a fatty oil, and at least one selected from the group consisting of fine powders and surfactants. Bacterial powders, fatty oils, micropowder and surfactants will be described in detail below.
  • Bacterial powder is a general term for dried bacterial cells.
  • a method for drying the cells for example, freeze-drying or spray-drying can be used, but the method is not limited thereto.
  • Freeze-drying is a method of drying at a low temperature of about ⁇ 20 ° C. to ⁇ 160 ° C., usually under a reduced pressure of about 1 to 60 Pa, using a freeze-drying device, liquid nitrogen, or the like.
  • Spray drying is a method in which a liquid is atomized by an atomizing device and the droplets are sprayed into a relatively high temperature heating stream to evaporate and dry the water.
  • the bacterial powder may be in a state in which only the bacterial cells are contained, or in a state in which the bacterial cells and components other than the bacterial cells are contained.
  • a freeze-protecting agent, a freeze-drying protective agent, a spray-drying protective agent, and a carrier can be used as the components other than the bacterial cells.
  • the bacterial powder may be dispersed in a doubling agent, an excipient or a carrier that has been used as a material for pharmaceuticals or foods and drinks.
  • the doubler, the excipient or the carrier include starch, starch decomposition products or dextrin.
  • the starch include corn starch, potato starch and tapioca starch.
  • the bacterial powder preferably contains at least one selected from the group consisting of live lactic acid bacteria, dead lactic acid bacteria, live bifidobacteria, and dead bifidobacteria.
  • Lactic acid bacteria are a general term for bacteria that produce lactic acid by metabolism, which belong to the Firmicutes phylum of the bacterial domain.
  • the lactic acid bacterium among the bacteria belonging to the Firmicutes phylum that produce lactic acid by metabolism, those belonging to the order Lactobacillus of the order Bacillus are preferable, and those belonging to Aerococcaceae, Carnobacterium, Enterococcaceae, Streptococcus, Lactobacillus Those belonging to the family, Aerococcaceae or Streptococcus are more preferable.
  • Lactobacillus gasseri belonging to the family Lactobacillus, Lactobacillus gasseri, L. acidofilus, L. herveticus, Lactobacillus paracasei (L. paracasei) L. casei, Lactobacillus ramunosus, Lactobacillus delbrucii, Lactobacillus delbrewy subspecies bulgarix -Lactobacillus bacteria such as L. plantarum can be mentioned.
  • Lactic acid bacteria belonging to the family Enterococcus include Enterococcus faecalis and E. coli. Examples include Enterococcus faecium bacteria such as E. faecium.
  • lactic acid bacteria belonging to the family Streptococcus examples include Lactococcus lactis, Lactococcus lactis. Examples thereof include Lactococcus bacterium such as L. lactis subspecies cremoris and Streptococcus thermophilus such as Streptococcus thermophilus.
  • Examples of the lactic acid bacterium belonging to the Leuconostocaceae family include Leuconostoc genus bacteria such as Leuconostoc mesenteroides and Leuconostoc mesenteroides subspecies cremoris.
  • the lactic acid bacterium at least one selected from the group consisting of the above-mentioned bacterial species is preferable. Further, as the lactic acid bacterium, a bacterial strain whose genus name (genus) or species name (epithet) has not been identified, or a new type of bacterial strain may be used. Lactic acid bacteria can be used in both live and dead states. The form of the lactic acid bacterium may be frozen, lyophilized or spray-dried.
  • the lactic acid bacterium may be in a state in which only the lactic acid bacterium cell is contained, and the lactic acid bacterium cell contains a component other than the bacterial cell (for example, a freeze-protecting agent, a freeze-drying protective agent, a spray-drying protective agent, etc.). Further, it may be in a state of being dispersed in a dipposition agent.
  • a freeze-protecting agent for example, a freeze-protecting agent, a freeze-drying protective agent, a spray-drying protective agent, etc.
  • a dipposition agent for example, a freeze-protecting agent, a freeze-drying protective agent, a spray-drying protective agent, etc.
  • starches such as corn starch, potato starch, tapioca starch, starch decomposition products, dextrin, malt dextrin and the like can be used.
  • Lactobacillus gasseri is not particularly limited as long as it exerts a beneficial effect on the host. Specifically, Lactobacillus gasseri is not particularly limited as long as it exerts a beneficial effect on the host, either alone or in combination with other active ingredients. Specific examples of Lactobacillus gasseri include NITE BP-01669, ATCC 33323, DSM 20243, JCM 1131, SBT 2055, and OLL 2716. As Lactobacillus gasseri, NITE BP-01669 is particularly preferable. Lactobacillus gasseri may be used alone or in combination of two or more strains.
  • Lactobacillus acidophilus is not particularly limited as long as it exerts a beneficial effect on the host. Specifically, Lactobacillus acidophilus is not particularly limited as long as it exerts a beneficial effect on the host, either alone or in combination with other active ingredients. Specific examples of Lactobacillus acidophilus include NITE BP-01695, ATCC 4356, DSM 20078, JCM 1132, and YIT 0168 and YIT 0154. As Lactobacillus acidophilus, NITE BP-01695 is particularly preferable. Lactobacillus acidophilus may be used alone or in combination of two or more strains.
  • Lactobacillus herbeticus is not particularly limited as long as it exerts a beneficial effect on the host. Specifically, Lactobacillus herbeticus is not particularly limited as long as it exerts a beneficial effect on the host, either alone or in combination with other active ingredients. Specific examples of Lactobacillus herbeticus include NITE BP-01671, ATCC 15009, DSM 20057, JCM 1120, and SBT 2171. As Lactobacillus herbeticus, NITE BP-01671 is particularly preferable. Lactobacillus herbeticus may be used alone or in combination of two or more strains.
  • Lactobacillus paracasei is not particularly limited as long as it exerts a beneficial effect on the host. Specifically, Lactobacillus paracasei is not particularly limited as long as it exerts a beneficial effect on the host, either alone or in combination with other active ingredients. Specific examples of Lactobacillus paracasei include NITE BP-01633, ATCC 25302, DSM 5622, JCM 8130, ATCC 25599, DSM 20258, and JCM 1171. As the Lactobacillus paracasei, NITE BP-01633 is particularly preferable. Lactobacillus paracasei may be used alone or in combination of two or more strains.
  • the cells of lactic acid bacteria can be easily obtained by culturing the lactic acid bacteria.
  • the culture method is not particularly limited as long as the lactic acid bacteria can grow.
  • the culturing method for example, the method usually used for culturing lactic acid bacteria can be used as it is or after being appropriately modified.
  • the culture temperature is preferably 25 to 50 ° C, more preferably 35 to 42 ° C.
  • Culturing is preferably carried out under anaerobic conditions.
  • the culture can be carried out while aerating a non-oxidizing gas such as carbon dioxide. Further, the culture may be carried out under microaerobic conditions such as liquid static culture.
  • the culture may be carried out, for example, until the lactic acid bacteria grow to a desired degree.
  • the medium used for culturing is not particularly limited as long as lactic acid bacteria can grow.
  • a medium usually used for culturing lactic acid bacteria can be used as it is or after being appropriately modified. That is, as the carbon source, for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolyzate, and waste sugar honey can be used depending on the assimilation property. It can also be cultured in a medium containing milk protein such as casein, whey, or a decomposition product thereof.
  • an ammonium salt such as ammonia, ammonium sulfate, ammonium chloride, ammonium nitrate or a nitrate
  • an ammonium salt such as ammonia, ammonium sulfate, ammonium chloride, ammonium nitrate or a nitrate
  • the inorganic salts for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate and the like can be used.
  • organic components such as peptone, soybean flour, defatted soybean meal, meat extract, and yeast extract may be used.
  • MRS medium de Man, Rogosa, and Sharp medium
  • the genus Bifidobacterium is the genus name of a group of bacteria belonging to the order Bifidobacterium in the phylum Actinobacteria of the bacterial domain.
  • Bifidobacterium genus bacteria examples include Bifidobacterium longum subspecies infantis, Bifidobacterium breve, and Bifidobacterium longum.
  • B. longum subspecies longum Bifidobacterium longum subspecies swiss (B. longum subspecies suis), Bifidobacterium longum subspecies lactis (B. longum subspecies lactis) subsp.
  • Lactis Lactis, Bifidobacterium longum subspecies animalis, Bifidobacterium longum, Bifidobacterium longum adolecentis, Bifidobacterium longum, Bifidobacterium longum, Bifidobacterium longum, Bifidobacterium longum (B) Species dolongum), and Bifidobacterium longum (B. thermophilum).
  • Bifidobacterium genus bacteria include Bifidobacterium longum subspecies infantis, Bifidobacterium longum, and Bifidobacterium longum.
  • Bifidobacterium longum subspecies longum Bifidobacterium longum subspecies swiss, Bifidobacterium longum subspecies lactis. It is preferable to use at least one selected from the group consisting of lactis) and Bifidobacterium longum (B. bifidum), and it is preferable to use Bifidobacterium longum subspecies infantis (B. longum subsp.). Infantis), Bifidobacterium longum (B. long), Bifidobacterium longum subspecies longum (B. longum subsp. Longum), Bifidobacterium longum subspecies lactis (B. longum subspecies lacticis).
  • Bifidobacterium spp. Can be used alone or in combination of two or more.
  • a combination when a bacterium belonging to the genus Bifidobacterium is used in combination a combination of one or more of each subspecies of Bifidobacterium longum and Bifidobacterium breve is preferable.
  • Bifidobacterium spp. Can be used in both live and dead states. The form of Bifidobacterium can be frozen, lyophilized or spray-dried. Furthermore, Bifidobacterium spp. Are only cells of Bifidobacterium spp., And components other than the cells of Bifidobacterium spp. (For example, freeze-protecting agent, lyophilization protective agent, spray drying). Protective agent, etc.) may be contained.
  • starches such as corn starch, potato starch, tapioca starch, starch decomposition products, dextrin, malt dextrin and the like can be used.
  • Bifidobacterium longum subspecies infantis is not particularly limited as long as it exerts a beneficial effect on the host. Specifically, Bifidobacterium longum subspecies infantis is not particularly limited as long as it exerts a beneficial effect on the host, either alone or in combination with other active ingredients. Specific examples of Bifidobacterium longum subspecies infantis include NITE BP-02623, ATCC 15697, ATCC 15702, DSM 20088, and JCM 1222. As the Bifidobacterium longum subspecies infantis, NITE BP-02623 is particularly preferable. Bifidobacterium longum subspecies infantis may be used alone or in combination of two or more strains.
  • Bifidobacterium breve is not particularly limited as long as it exerts a beneficial effect on the host. Specifically, Bifidobacterium breve is not particularly limited as long as it exerts a beneficial effect on the host, either alone or in combination with other active ingredients. Specific examples of the Bifidobacterium breve include NITE BP-02622, FERM BP-11175, ATCC 15700, ATCC 15698, DSM 20213, DSM 24706, DSM 13692, DSM 24732, DSM 24736, DSM 16604, and JCM.
  • NITE BP-02622 is particularly preferable.
  • Bifidobacterium breve may be used alone or in combination of two or more strains.
  • Bifidobacterium longum subspecies longum Bifidobacterium longum subspecies longum is not particularly limited as long as it exerts a beneficial effect on the host. Specifically, Bifidobacterium longum subspecies longum is not particularly limited as long as it exerts a beneficial effect on the host, either alone or in combination with other active ingredients. Specific examples of Bifidobacterium longum subspecies longum include NITE BP-02621, ATCC 15707, ATCC 25962, DSM 20219, and JCM 1217. As the Bifidobacterium longum subspecies longum, NITE BP-02621 is particularly preferable. Bifidobacterium longum subspecies longum may be used alone or in combination of two or more strains.
  • Bifidobacterium Longum Subspecies Switzerland Bifidobacterium longum subspecies Switzerland is not particularly limited as long as it exerts a beneficial effect on the host. Specifically, Bifidobacterium longum subspecies Switzerland is not particularly limited as long as it exerts a beneficial effect on the host, either alone or in combination with other active ingredients. Specific examples of Bifidobacterium Longum Subspecies Switzerland include ATCC 27533, ATCC 27532, DSM 20211, and JCM 1269. The ATCC 27533 is particularly preferred as the Bifidobacterium Longum Subspecies Switzerland. Bifidobacterium longum subspecies Switzerland may be used alone or in combination of two or more strains.
  • Bifidobacterium animalis subspecies lactis is not particularly limited as long as it exerts a beneficial effect on the host. Specifically, Bifidobacterium animalis subspecies lactis is not particularly limited as long as it exerts a beneficial effect on the host, either alone or in combination with other active ingredients. Specific examples of the Bifidobacterium animalis subspecies lactis include DSM 15954 and FERM P-21998. As the Bifidobacterium animalis subspecies lactis, DSM 15954 is particularly preferable. Bifidobacterium animalis subspecies lactis may be used alone or in combination of two or more strains.
  • a strain having a substantially same strain relationship with the strain stored in the strain preservation institution (culture collection) by the strain number may be used instead of ATCC 15707.
  • DSM 20219 or JCM 1217 may be used instead of ATCC 15707.
  • the identity of the 16S rRNA gene base sequence can be used.
  • the identity of the 16S rRNA gene base sequence when the strains have substantially the same relationship is preferably 99.86% or more, more preferably 99.93% or more, still more preferably 100%.
  • the 16S rRNA gene base sequence is 100% identical and the microbiological properties such as assimilation are the same.
  • a derivative strain of the strain may be used instead of the strain specified by the exemplified strain number.
  • Derivative strains include strains artificially bred from preserved strains and naturally occurring strains from preserved strains.
  • Examples of the breeding method include modification by a genetic engineering method and modification by mutation treatment. Mutation treatment includes, for example, X-ray irradiation, ultraviolet irradiation, or N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), ethylmethanesulfonate (EMS), methylmethanesulfonate (MMS), or the like. Treatment with a mutant agent can be mentioned.
  • the strain naturally generated from the preserved strain include a mutant strain naturally generated during the use of the preserved strain.
  • the derivative strain may be constructed by modifying one strain or by modifying two or more strains.
  • Bifidobacterium genus bacterium a commercially available product may be used, or a product obtained by appropriately manufacturing may be used.
  • a commercially available product for example, Bifidobacterium longum subspecies longum NITE BP-02621, Bifidobacterium Breve NITE BP-02622, Bifidobacterium longum subspecies infantis NITE BP- 02623, Bifidobacterium animalis subspecies lactis BB-12 (DSM 15954) can be mentioned.
  • Bifidobacterium bacterium cells can be easily obtained by culturing Bifidobacterium genus bacteria.
  • the culture method is not particularly limited as long as Bifidobacterium can grow.
  • the culture temperature is preferably 25 to 50 ° C, more preferably 35 to 42 ° C.
  • Culturing is preferably carried out under anaerobic conditions.
  • the culture can be carried out while aerating a non-oxidizing gas such as carbon dioxide.
  • the culture may be carried out under microaerobic conditions such as liquid static culture. Culturing may be carried out, for example, until the bacteria of the genus Bifidobacterium grow to a desired degree.
  • the medium used for culturing is not particularly limited as long as Bifidobacterium spp. Can grow.
  • a medium usually used for culturing bifidobacteria can be used as it is or after being appropriately modified.
  • the carbon source for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolyzate, and waste sugar honey can be used depending on the assimilation property. It can also be cultured in a medium containing milk protein such as casein, whey, or a decomposition product thereof.
  • an ammonium salt such as ammonia, ammonium sulfate, encaammonium, ammonium nitrate or a nitrate can be used.
  • inorganic salts for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate and the like can be used.
  • organic components such as peptone, soybean flour, defatted soybean meal, meat extract, and yeast extract may be used.
  • MRS medium de Man, Rogosa, and Sharp medium
  • NITE NITE Patent Microorganisms Development
  • FERM NITE Patent Microorganisms Development
  • ATCC American Type Culture Collection
  • DSM Deutsche Sammlung von Mikurogangismen und Zellkulturen GmbH
  • JCM Japan Collection of Microorganisms
  • Riken BRC NCC Nestlé S.A.
  • SBT MEGMILK Snow Brand Co., Ltd. , Ltd.
  • OLL Meiji Co., Ltd. , Ltd.
  • R LALLEMAND Inc.
  • the bacterial powder may be a live bacterium or a dead bacterium, but when the bacterial powder is a live bacterium, it can be expected to function as "probiotics".
  • probiotics is a term proposed for antibiotics (antibiotics), and the etymology is probiotics, which means symbiosis.
  • antibiotics antibiotics
  • probiotics which means symbiosis.
  • the widely accepted definition of probiotics is "living microbes that positively affect host health by improving the balance of the intestinal flora.”
  • the content of bacterial powder in the composition of the present invention is preferably 0.5 to 10% by mass, more preferably 1 to 5% by mass, based on the total mass of the composition.
  • the advantageous effect due to the content of the bacterial powder in the composition of the present invention can be better exhibited.
  • the content of the bacterial powder is 10% by mass or less with respect to the total mass of the composition, the balance between the advantageous effect and the cost due to the content of the bacterial powder in the composition of the present invention becomes better.
  • the fatty oil in the present invention is preferably a liquid oil in at least a part of the range of 0 to 40 ° C. in the process of distributing the composition of the present invention, and is preferably in the range of 0 to 40 ° C. It is more preferable that the oil is liquid over the entire area.
  • edible oil is preferable.
  • edible oils include hazelnut oil, olive oil, cherry oil, pumpkin oil, rice bran oil, soybean oil, corn oil, sunflower oil, rapeseed oil, benibana oil (saflower oil), palm oil (kofune palm oil, sawtooth oil, etc.) Includes), palm oil, palm kernel oil, medium chain fatty acid triglyceride (MCT), docosahexaenoic acid (DHA), icosapentic acid (EPA), flaxseed oil, egoma oil (perilla oil), rice germ oil, wheat germ oil, coconut Oil, cotton seed oil, peanut oil, sesame oil, almond oil, cashew oil, macadamia nut oil, mongongo oil, pecan oil, pine seed oil, pistachio oil, walnut oil, gourd seed oil, buffalo pumpkin oil, pumpkin seed oil, watermelon seed Oil, acai berry extract, cassis oil, rurigisa seed oil, evening primrose oil
  • fatty oil at least one selected from the group consisting of olive oil, rice bran oil, soybean oil, corn oil, sunflower oil, Benibana oil (saflower oil), and medium chain fatty acid triglyceride (MCT) is preferable, and corn oil, At least one selected from the group consisting of sunflower oil and medium-chain triglyceride (MCT) is more preferable, and medium-chain triglyceride (MCT) is particularly preferable.
  • the fat oil is preferably contained in an amount of 90% by mass or more, more preferably 92% by mass or more, and further preferably 95% by mass or more, based on the total mass of the composition.
  • the micropowder and surfactant act as anti-caking agents.
  • the anti-caking agent has an action of preventing or eliminating caking.
  • the fine powder is a fine-sized powder of an organic substance or an inorganic substance, and a fine-sized powder of an organic substance is preferable.
  • micro-sized powders of organic substances include microcrystalline cellulose.
  • Microcrystalline cellulose is high-purity cellulose obtained by hydrolyzing and purifying pulp with an acid.
  • the average particle size of the microcrystalline cellulose particles is D50, preferably 1 to 200 ⁇ m, more preferably 5 to 100 ⁇ m.
  • the average particle size (D50) of the fine particles is a 50% volume particle size calculated from the volume distribution obtained by the laser diffraction / scattering method.
  • micro-sized powders of inorganic substances include tricalcium phosphate and fine silicon dioxide.
  • Tricalcium phosphate is a salt of phosphoric acid and calcium represented by the chemical formula Ca 3 (PO 4 ) 2.
  • Tricalcium phosphate has three types of polymorphs, but in the composition of the present invention, ⁇ -tricalcium phosphate ( ⁇ -TCP), which is a low-temperature polyform, is observed.
  • Fine-grained silicon dioxide is a fine particle of silica.
  • tricalcium phosphate is particularly preferable.
  • the average particle size of the tricalcium phosphate particles is D50, preferably 1 to 200 ⁇ m, and more preferably 1 to 50 ⁇ m.
  • the micropowder preferably contains at least one selected from the group consisting of microcrystalline cellulose and tricalcium phosphate.
  • the fine powder and the surfactant are suitable for use as an anti-caking agent for bacterial powder.
  • the surfactant is preferably at least one selected from the group consisting of anionic surfactants and nonionic surfactants having an HLB value of less than 7.
  • anionic surfactant examples include a carboxylic acid type anionic surfactant, a linear sodium alkylbenzene sulfonate, a sulfonic acid type anionic surfactant, a sulfate ester type anionic surfactant and a phosphoric acid ester type anionic surfactant. Be done.
  • the anionic surfactant at least one selected from the group consisting of fatty acid salts having 12 to 18 carbon atoms is preferable, at least one selected from the group consisting of stearic acid metal salts is more preferable, and stearic acid is more preferable. Alkaline earth metal salts are more preferred, and calcium stearate or magnesium stearate is particularly preferred.
  • the anionic surfactant may be used alone or in combination of two or more.
  • Nonion surfactant with HLB value less than 7 is preferably a fatty acid ester having an HLB value of less than 7, and is selected from the group consisting of a sucrose fatty acid ester having an HLB value of less than 7 and a glycerin fatty acid ester having an HLB value of less than 7. At least one selected from the group consisting of sucrose fatty acid esters having an HLB value of less than 7 is even more preferable.
  • Nonionic surfactants having an HLB value of less than 7 can be used alone or in combination of two or more.
  • the content of the fine powder and the surfactant in the composition of the present invention is preferably 0.01 to 10% by mass, preferably 0.1 to 10% by mass, based on the total mass of the fine powder and the surfactant. It is more preferably from 5% by mass, still more preferably from 0.5 to 2% by mass.
  • composition of the present invention may further contain additives in addition to the above-mentioned components.
  • additives include antioxidants, excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, diluents and the like.
  • Vitamin E is preferred as the antioxidant.
  • Vitamin E is a fat-soluble vitamin and is easily dissolved in the fatty oil in the composition.
  • the composition of the present invention may be, for example, a supplement composition, a beverage composition, a food composition, a pharmaceutical composition, or a feed composition, but is preferably used as a supplement composition.
  • the composition of the present invention may be ingested as it is, or the composition of the present invention may be added to a supplement, beverage, food, pharmaceutical or feed and ingested. May be good.
  • the composition of the present invention is added to a supplement, beverage, food, pharmaceutical or feed, it is preferable to utilize the composition of the present invention by dropping a few drops into the beverage, food, pharmaceutical or feed.
  • the composition of the present invention can be produced by mixing bacterial powder, fatty oil, and at least one selected from the group consisting of fine powders and surfactants in an arbitrary order.
  • the composition of the present invention can also be produced by mixing a suspension containing bacterial powder and fatty oil with at least one selected from the group consisting of fine powders and surfactants.
  • the mixing method is not particularly limited. For example, by stirring, bacterial powder, fatty oil, and at least one selected from the group consisting of fine powders and surfactants can be mixed.
  • the mixing order thereof is not particularly limited. It may be contained in a suspension containing bacterial powder and fatty oil, or may be added when mixing at least one selected from the group consisting of fine powder and surfactant.
  • Bifidobacterium infantis NITE BP-02623 is inoculated into a medium containing a protein, amino acid and sugar source, cultured at 32 to 41 ° C. for 5 to 24 hours, and then from the culture medium.
  • Bacterial cells (wet cells) were collected by centrifugation.
  • a freeze-dryer manufactured by Kyowa Vacuum Co., Ltd.
  • freeze-drying was carried out for 18 to 96 hours, and the bacterial cell mass after the completion of freeze-drying was physically crushed to obtain a freeze-dried powder.
  • the obtained freeze-dried powder and tapioca starch were doubled at a ratio of 1: 3 (w / w) to obtain Bifidobacterium bacterial powder.
  • Bifidobacterium longum subspecies longum Bifidobacterium longum subsp. Longum
  • NITE BP-02621 is inoculated into a medium containing a protein, amino acid and sugar source, and cultured at 32 to 41 ° C. for 5 to 24 hours. After that, bacterial cells (wet bacterial cells) were collected by centrifugation from the culture medium. Using a freeze-dryer (manufactured by Kyowa Vacuum Co., Ltd.), freeze-drying was carried out for 18 to 96 hours, and the bacterial cell mass after the completion of freeze-drying was physically crushed to obtain a freeze-dried powder. The obtained freeze-dried powder and corn starch were doubled at a ratio of 1: 3 (w / w) to obtain Bifidobacterium spp.
  • Lactobacillus gasseri NITE BP-01669 is inoculated into a medium containing a protein, amino acid and sugar source, cultured at 32-41 ° C for 5-24 hours, and then centrifuged from the culture solution. The body (wet cells) was collected. Using a freeze-dryer (manufactured by Kyowa Vacuum Co., Ltd.), freeze-drying was carried out for 18 to 96 hours, and the cell mass after the completion of freeze-drying was physically crushed to obtain a freeze-dried powder. The obtained freeze-dried powder and corn starch were doubled at a ratio of 1: 3 (w / w) to obtain lactic acid bacteria powder.
  • Lactobacillus acidophilus NITE BP-01695 is inoculated into a medium containing a protein, amino acid and sugar source, cultured at 32 to 41 ° C. for 5 to 24 hours, and then centrifuged from the culture solution. The body (wet cells) was collected. Using a freeze-dryer (manufactured by Kyowa Vacuum Co., Ltd.), freeze-drying was carried out for 18 to 96 hours, and the bacterial cell mass after the completion of freeze-drying was physically crushed to obtain a freeze-dried powder. The obtained freeze-dried powder and corn starch were doubled at a ratio of 1: 3 (w / w) to obtain lactic acid bacteria powder.
  • a freeze-dryer manufactured by Kyowa Vacuum Co., Ltd.
  • Lactobacillus paracasei NITE BP-01633 is inoculated into a medium containing a protein, amino acid and sugar source, cultured at 32 to 41 ° C. for 5 to 24 hours, and then centrifuged from the culture solution. The body (wet cells) was collected. Using a freeze-dryer (manufactured by Kyowa Vacuum Co., Ltd.), freeze-drying was carried out for 18 to 96 hours, and the bacterial cell mass after the completion of freeze-drying was physically crushed to obtain a freeze-dried powder. The obtained freeze-dried powder and maltodextrin were doubled at a ratio of 1: 3 (w / w) to obtain lactic acid bacteria powder.
  • a freeze-dryer manufactured by Kyowa Vacuum Co., Ltd.
  • Lactobacillus herveticus NITE BP-01671 was inoculated into a medium containing a protein, amino acid and sugar source, cultured at 32 to 41 ° C. for 5 to 24 hours, and then centrifuged from the culture solution. The body (wet cells) was collected. The concentrated bacterial solution and the starch decomposition product were mixed at a ratio of 1: 4 (solid content conversion ratio, w / w) and then spray-dried with a spray dryer to obtain lactic acid bacteria powder.
  • Bifidobacterium longum subspecies infantis NITE BP-02623 is inoculated into a medium containing a protein, amino acid and sugar source and cultured at 32-41 ° C for 5-24 hours. After that, bacterial cells (wet bacterial cells) were collected by centrifugation from the culture medium. Using a freeze-dryer (manufactured by Kyowa Vacuum Co., Ltd.), freeze-drying was carried out for 18 to 96 hours, and the bacterial mass after the completion of freeze-drying was physically crushed to obtain a freeze-dried powder.
  • a freeze-dryer manufactured by Kyowa Vacuum Co., Ltd.
  • Example A1 is a comparative example, and Examples A2 to A22 are Examples.
  • Bacterial powder, fine powder or surfactant, and fatty oil were mixed at the ratio (unit: mass%) shown in Table 2 or Table 3 to prepare a uniform dispersion using a magnetic stirrer.
  • B-100D was added to fatty oil, dissolved in a warm bath at 90 ° C., returned to room temperature, and then bacterial powder was added and mixed uniformly.
  • the dispersibility was evaluated according to the evaluation method described above. The evaluation results are shown in Tables 2 and 3.
  • Examples A2 to A22 containing the fine powder or the surfactant were superior in dispersibility of the bacterial powder as compared with Example A1 not containing the fine powder or the surfactant.
  • the dispersibility evaluation was B, and the dispersibility of bacterial powder was better than that of Example A1.
  • Examples A11 to A16 containing nonionic surfactants (B-100D, S-170) having an HLB value of less than 7 contain nonionic surfactants (S-770, S-1570) having an HLB value of 7 or more.
  • the dispersibility of the bacterial powder was better than that of Examples A17 to A22.
  • Example B1 is a comparative example, and Examples B2 to B9 are Examples.
  • Bacterial powder, fine powder or surfactant, and fatty oil were mixed at the ratio (unit: mass%) shown in Table 4, and a uniform dispersion was prepared using a magnetic stirrer.
  • surfactants L-195 and POS-135 were added to fatty oil, dissolved in a warm bath at 90 ° C., returned to room temperature, and then bacterial powder was added and mixed uniformly.
  • the dispersibility was evaluated according to the evaluation method described above. The evaluation results are shown in Table 4.
  • Examples B2 to B9 containing the fine powder or the surfactant were superior in dispersibility of the bacterial powder as compared with Example B1 not containing the fine powder or the surfactant.
  • Example B7 containing B-370F (HLB value 3) as a nonionic surfactant, nonionic surfactant
  • the dispersibility evaluation was A, and the dispersibility of bacterial powder was particularly excellent.
  • Example C1 is a comparative example, and Examples C2 to C11 are Examples.
  • Bacterial powder, fine powder or surfactant, and fatty oil were mixed at the ratio (unit: mass%) shown in Table 5 to prepare a uniform dispersion using a magnetic stirrer.
  • B-100D was added to fatty oil, dissolved in a warm bath at 90 ° C., returned to room temperature, and then bacterial powder was added and mixed uniformly.
  • the dispersibility was evaluated according to the evaluation method described above. The evaluation results are shown in Table 5.
  • Examples C2 to C11 containing fine powder or a surfactant were superior in dispersibility of bacterial powder as compared with Example C1 not containing these.
  • the dispersibility evaluation was A, and the dispersibility of the bacterial powder was particularly excellent.
  • Example D1 to Example D12 ⁇ Example D1 to Example D12>
  • Examples D1, Example D3, Example D5, Example D7, Example D9 and Example D11 are comparative examples
  • Example D2, Example D4, Example D6, Example D8, Example D10 and Example D12 are examples.
  • Bacterial powder, fine powder or surfactant, and fatty oil were mixed at the ratio (unit: mass%) shown in Table 6 to prepare a uniform dispersion using a magnetic stirrer. Using the prepared composition, the dispersibility was evaluated according to the evaluation method described above. The evaluation results are shown in Table 6.
  • Example D2 Example D4, Example D6, Example D8, Example D10 and Example D12 in which Ca stearate was blended
  • the dispersibility evaluation was A or B, and the dispersibility of bacterial powder was good.
  • Ca stearate was added between an example using lyophilized bacterial powder (Example D2, Example D4, Example D6, Example D8, Example D10) and an example using spray-dried bacterial powder (Example D12). There was no significant difference in dispersibility.
  • Example E1 is a comparative example
  • Example E2 is an example.
  • Bacterial powder, fine powder or surfactant, and fatty oil were mixed at the ratio (unit: mass%) shown in Table 7 to prepare a uniform dispersion using a magnetic stirrer. Using the prepared composition, the dispersibility was evaluated according to the evaluation method described above. The evaluation results are shown in Table 7.
  • Example E2 containing Ca stearate had a dispersibility evaluation of B, and the dispersibility of bacterial powder was good. Even when the bacterial powder in a state in which the doubling agent was not mixed was used, the dispersibility was improved by adding Ca stearate.
  • Example F1 is a comparative example
  • Example F2 is an example.
  • a commercially available supplement composition (Baby ProbioBifizus M1, manufactured by Bean Stalk Snow Co., Ltd.) is used as it is (Example F1), or 1.0% by mass of Ca stearate is added (Example F2) to prepare an evaluation composition.
  • the above supplement composition is a composition containing bifidobacteria powder (Bifidobacterium animalis subspecies lactis BB-12: DSM 15954), sunflower oil, an antioxidant (vitamin E), and citric acid as raw materials. is there.
  • the prepared evaluation composition was used to evaluate the dispersibility according to the evaluation method described above. The evaluation results are shown in Table 8.
  • Micro powder Microcrystalline Cellulose ... Theoras FD-F20 (manufactured by Asahi Kasei Corporation) Tricalcium Phosphate ... Tricalcium Phosphate (manufactured by Taihei Kagaku Sangyo Co., Ltd.) Fine silicon dioxide ... Silo page 720 (manufactured by Fuji Silysia Chemical Ltd.)
  • Sucrose fatty acid ester (Ryoto Sugar Ester P-170, manufactured by Mitsubishi Chemical Foods Co., Ltd .; HLB value 1) O-170 ... Sucrose fatty acid ester (Ryoto sugar ester O-170, manufactured by Mitsubishi Chemical Foods Co., Ltd .; HLB value 1) L-195 ... Sucrose fatty acid ester (Ryoto sugar ester L-195, manufactured by Mitsubishi Chemical Foods Co., Ltd .; HLB value 1) B-370F ... Sucrose fatty acid ester (Ryoto Sugar Ester B-370F, manufactured by Mitsubishi Chemical Foods Co., Ltd .; HLB value 3) ER-190 ...
  • Sucrose fatty acid ester (Ryoto Sugar Ester ER-190, manufactured by Mitsubishi Chemical Foods Co., Ltd .; HLB value 1) POS-135 ... Sucrose fatty acid ester (Ryoto Sugar Ester POS-135, manufactured by Mitsubishi Chemical Foods Co., Ltd .; HLB value 1) S-770 ... Sucrose fatty acid ester (Ryoto Sugar Ester S-770, manufactured by Mitsubishi Chemical Foods Co., Ltd .; HLB value 7) S-1570 Sucrose fatty acid ester (Ryoto Sugar Ester S-1670, manufactured by Mitsubishi Chemical Foods Co., Ltd .; HLB value 16)
  • composition of the present invention can be used as a supplement composition by ingesting it as it is or adding it to foods.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/JP2020/012524 2019-10-17 2020-03-19 組成物、製造方法及び使用 Ceased WO2021075073A1 (ja)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN202510128251.6A CN120570388A (zh) 2019-10-17 2020-03-19 包含菌粉的组合物、制造方法及应用
KR1020267008192A KR20260043146A (ko) 2019-10-17 2020-03-19 조성물, 제조 방법 및 사용
ES20877757T ES2997284T3 (en) 2019-10-17 2020-03-19 Composition, production method, and usage
JP2021552091A JP7086309B2 (ja) 2019-10-17 2020-03-19 組成物、製造方法及び使用
CN202211398838.1A CN115624181A (zh) 2019-10-17 2020-03-19 组合物、制造方法及应用
NZ784460A NZ784460B2 (en) 2020-03-19 Composition, production method, and usage
AU2020366736A AU2020366736B2 (en) 2019-10-17 2020-03-19 Composition, production method, and usage
KR1020227003277A KR20220026595A (ko) 2019-10-17 2020-03-19 조성물, 제조 방법 및 사용
EP20877757.3A EP4046499B1 (en) 2019-10-17 2020-03-19 Composition, production method, and usage
CN202080057079.5A CN114222503A (zh) 2019-10-17 2020-03-19 组合物、制造方法及应用
PL20877757.3T PL4046499T3 (pl) 2019-10-17 2020-03-19 Kompozycja, sposób wytwarzania i zastosowanie
US16/987,061 US20210113631A1 (en) 2019-10-17 2020-08-06 Composition, production method for producing the same, and method of preventing caking
US17/688,035 US20220193159A1 (en) 2019-10-17 2022-03-07 Composition, production method for producing the same, and method of preventing caking
JP2022091694A JP7575424B2 (ja) 2019-10-17 2022-06-06 組成物及び製造方法
JP2024181969A JP2025010582A (ja) 2019-10-17 2024-10-17 組成物及び製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916346P 2019-10-17 2019-10-17
US62/916,346 2019-10-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/987,061 Continuation-In-Part US20210113631A1 (en) 2019-10-17 2020-08-06 Composition, production method for producing the same, and method of preventing caking

Publications (1)

Publication Number Publication Date
WO2021075073A1 true WO2021075073A1 (ja) 2021-04-22

Family

ID=75537522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/012524 Ceased WO2021075073A1 (ja) 2019-10-17 2020-03-19 組成物、製造方法及び使用

Country Status (10)

Country Link
US (2) US20210113631A1 (cg-RX-API-DMAC7.html)
EP (1) EP4046499B1 (cg-RX-API-DMAC7.html)
JP (3) JP7086309B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220026595A (cg-RX-API-DMAC7.html)
CN (3) CN114222503A (cg-RX-API-DMAC7.html)
AU (1) AU2020366736B2 (cg-RX-API-DMAC7.html)
ES (1) ES2997284T3 (cg-RX-API-DMAC7.html)
HU (1) HUE069293T2 (cg-RX-API-DMAC7.html)
PL (1) PL4046499T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021075073A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025225690A1 (ja) * 2024-04-25 2025-10-30 森永乳業株式会社 菌末の製造方法、及び噴霧乾燥に供される組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562908A (en) * 1979-06-20 1981-01-13 Nikken Kagaku Kk Preparation of stable live bacterial pharmaceutical remedy
JP2000157168A (ja) * 1998-04-01 2000-06-13 Nisshin Oil Mills Ltd:The 油性組成物及びその製造方法
JP2006501281A (ja) * 2002-09-26 2006-01-12 プロバイオヘルス・エルエルシー 油乳化プロバイオティックカプセル封入物のプレバイオティックおよび保存的使用
US20180235271A1 (en) 2017-02-21 2018-08-23 Jarrow Formulas, Inc. Probiotic dietary supplement formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11225690A (ja) * 1997-12-10 1999-08-24 House Foods Corp ゲル状食品用ベース及びこれを用いたゲル状食品の製造方法
US6190680B1 (en) * 1998-04-01 2001-02-20 The Nisshin Oil Mills, Ltd. Oily composition and process for producing the same
JP4417039B2 (ja) * 2002-06-28 2010-02-17 太陽化学株式会社 水中油滴型乳化組成物
US20080131515A1 (en) * 2006-12-01 2008-06-05 Fujifilm Corporation Emulsion composition, and foods and cosmetics containing the emulsion composition
JP2010168306A (ja) * 2009-01-22 2010-08-05 Kaneka Corp 粒子状組成物の製造方法
IT1400821B1 (it) 2009-03-09 2013-07-02 Probiotical Spa Sospensione oleosa contenente batteri probiotici per uso pediatrico
JP2012092094A (ja) 2010-09-30 2012-05-17 Wakamoto Pharmaceutical Co Ltd 油脂中に乳酸菌を含有する口腔用組成物
JP5650043B2 (ja) 2011-04-20 2015-01-07 森永乳業株式会社 生菌数測定方法
CN105338828A (zh) * 2013-06-26 2016-02-17 三菱化学食品株式会社 粉末组合物、该粉末组合物的制造方法和饮料
CN103689595A (zh) * 2013-12-12 2014-04-02 天津科技大学 一种乳酸菌软胶囊及其制备方法
EP3151686A2 (en) 2014-06-03 2017-04-12 Abbott Laboratories Potato based protein mixtures and nutritional compositions comprising potato protein
JP6297441B2 (ja) * 2014-07-31 2018-03-20 森永乳業株式会社 ビフィドバクテリウム属細菌含有カプセルおよびその製造方法
JP6893413B2 (ja) * 2015-06-01 2021-06-23 株式会社ロッテ 乳酸菌含有油脂組成物およびその製造方法
JP6961339B2 (ja) * 2015-12-18 2021-11-05 アサヒ飲料株式会社 微生物菌体含有飲料
WO2018174938A1 (en) * 2017-03-23 2018-09-27 Virun, Inc. Stable dry powders and emulsions containing probiotics and mucoadhesive protein
JP6971647B2 (ja) * 2017-06-14 2021-11-24 アサヒ飲料株式会社 微生物菌体含有炭酸飲料、および炭酸飲料における微生物菌体粉末の沈澱物または凝集物の分散性向上方法
CN108113003A (zh) * 2017-12-15 2018-06-05 浙江康诺邦健康产品有限公司 一种适合婴幼儿的益生菌软胶囊及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562908A (en) * 1979-06-20 1981-01-13 Nikken Kagaku Kk Preparation of stable live bacterial pharmaceutical remedy
JP2000157168A (ja) * 1998-04-01 2000-06-13 Nisshin Oil Mills Ltd:The 油性組成物及びその製造方法
JP2006501281A (ja) * 2002-09-26 2006-01-12 プロバイオヘルス・エルエルシー 油乳化プロバイオティックカプセル封入物のプレバイオティックおよび保存的使用
US20180235271A1 (en) 2017-02-21 2018-08-23 Jarrow Formulas, Inc. Probiotic dietary supplement formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4046499A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025225690A1 (ja) * 2024-04-25 2025-10-30 森永乳業株式会社 菌末の製造方法、及び噴霧乾燥に供される組成物

Also Published As

Publication number Publication date
NZ784460A (en) 2023-12-22
CN120570388A (zh) 2025-09-02
JPWO2021075073A1 (cg-RX-API-DMAC7.html) 2021-04-22
EP4046499C0 (en) 2024-11-13
US20220193159A1 (en) 2022-06-23
ES2997284T3 (en) 2025-02-17
EP4046499B1 (en) 2024-11-13
AU2020366736A1 (en) 2022-02-24
EP4046499A1 (en) 2022-08-24
EP4046499A4 (en) 2023-07-19
JP2025010582A (ja) 2025-01-22
CN115624181A (zh) 2023-01-20
US20210113631A1 (en) 2021-04-22
PL4046499T3 (pl) 2025-02-10
HUE069293T2 (hu) 2025-02-28
JP2022111196A (ja) 2022-07-29
JP7575424B2 (ja) 2024-10-29
KR20220026595A (ko) 2022-03-04
JP7086309B2 (ja) 2022-06-17
CN114222503A (zh) 2022-03-22
AU2020366736B2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CN103189499B (zh) 乳酸菌和/或双歧杆菌的存活能力提高剂
WO2005060937A1 (en) Compressed tablets comprising viable probiotic microorganisms
US20240228944A9 (en) Method for preparing bacterial products
CN107287136A (zh) 一种具有益生功能的益生固态乳酸菌菌剂的制备方法
KR102842609B1 (ko) 항염증, 항산화 및 항균 활성을 가지는 락토바실러스 플란타럼 beLP1 균주 및 이를 포함하는 조성물
JP2025010582A (ja) 組成物及び製造方法
JP7444949B2 (ja) 乳酸菌用培地
JP2008189572A (ja) インターロイキン12産生抑制剤
JP2020137456A (ja) 乳酸菌培養用培地
CN119110844A (zh) 高储存稳定性的微囊化微生物培养物制剂
KR100868777B1 (ko) Rs3 유형의 저항 전분에 대해 분해능이 있는비피도박테리움 아도레스센티스를 유효성분으로 함유하는것을 특징으로 하는 식품 조성물
JP7499704B2 (ja) 保存安定性と、耐胃液分解安定性を付与したプロバイオティクス組成物
JP7104045B2 (ja) 嚥下困難者用増粘組成物
KR101172839B1 (ko) 코팅 유산균의 제조방법 및 상기 코팅 유산균을 포함하는 보쌈용 수육의 제조방법
KR20260043146A (ko) 조성물, 제조 방법 및 사용
KR20180091603A (ko) 바이오폴리머를 이용한 프로바이오틱스 분말조성물 및 이의 제조방법
JP7602372B2 (ja) 高生残性微生物乾燥菌体の製造方法
WO2020189228A1 (ja) 腸内有用菌の増殖及び有機酸産生増強剤
KR20190019097A (ko) 바이오폴리머를 이용한 프로바이오틱스 분말조성물 및 이의 제조방법
Narayanan et al. Delivery of Probiotics by Encapsulation Using Spray Drying Technology and Evaluation of Its Powder Qualities
HK40017185A (en) Thickening composition for dysphagia patients
LT6202B (lt) Maistinio arba farmacinio biopreparato kompozicija
JP2000023663A (ja) 嫌気性菌の培養方法および培地

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20877757

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021552091

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227003277

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020366736

Country of ref document: AU

Date of ref document: 20200319

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020877757

Country of ref document: EP

Effective date: 20220517

WWR Wipo information: refused in national office

Ref document number: 1020227003277

Country of ref document: KR

WWC Wipo information: continuation of processing after refusal or withdrawal

Ref document number: 1020227003277

Country of ref document: KR